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Abstract The rate of long-term remissions after treatment of
peripheral T cell lymphomas (PTCL) with standard CHOP-like
protocols is unsatisfactory. A prospective multicenter phase II
trial was initiated in untreated patients with PTCL of all Inter-
national Prognostic Index-risk groups, evaluating alemtuzumab
consolidation in patientswith complete or good partial remission
after CHO(E)P-14 induction. Twenty-nine (70.7 %) of the 41
enrolled patients received alemtuzumab consolidation (133 mg
in total). The main grades 3–4 toxicities during alemtuzumab
therapy were infections and neutropenia with one potentially
treatment-related death. Complete responses were seen in
58.5 %, partial responses in 2.4 % and 29.3 % had progressive
disease. After a median observation time of 46 months, 19
patients have died, 16 of them due to lymphoma and/or salvage
therapy complications. Event-free and overall survival at 3 years
in the whole intent to treat population are 32.3 and 62.5 %,
respectively, and 42.4 and 75.1 % in the patients who received
alemtuzumab. In conclusion, application of a short course of
alemtuzumab after CHO(E)P-14 induction is feasible although
complicated by severe infections. A current phase III trial,
applying alemtuzumab as part of the initial chemotherapy pro-
tocol to avoid early progression, will further clarify its signifi-
cance for the therapeutic outcome.
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Introduction
Peripheral T cell lymphomas are rare [1], accounting for 5–
10% of all non-Hodgkin lymphomas inWestern countries [2].
The most frequent entities according to the WHO classifica-
tion are peripheral T cell lymphoma not otherwise specified
(PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL),
extranodal NK/T cell lymphoma and anaplastic large cell T
cell lymphoma (ALCL) with and without expression of ana-
plastic lymphoma kinase (ALK) [3].
Systemic PTCL follow an aggressive clinical course with
significantly less favourable outcome than aggressive B cell
lymphomas [4, 5]. The International Prognostic Index (IPI) [6]
also predicts outcome in PTCL; however, even in the best
category, the overall survival (OS) at 5 years is only 50 % [2],
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excluding patients with ALK+ALCL with an excellent out-
come in the IPI 0/1 categories [7].
Treatment with CHOP-like protocols results in overall
response rates of 60–70 % but unsatisfactory long-term remis-
sions [7] and a median 5-year OS of only 32% [3]. Dose-dense
CHOP-14 therapy with inclusion of etoposide was recently
shown in a retrospective analysis to improve outcome in pa-
tients <60 years with normal LDH [8], yielding a 3-year event-
free survival (EFS) of 71 versus 51 % for conventional CHOP
in ALK+ALCL patients. Although currently recommended as
consolidation for high-risk patients in first remission, contra-
dictory results are reported for up-front dose escalation follow-
ed by autologous stem cell transplantation (ASCT). Several
trials show OS rates comparable to those with conventional
regimens, in particular, when ALK+ALCL are excluded
[9–11]. Other authors report OS rates of 49 % at 5 years and
of 59 % at 4 years [12, 13]. In three prospective trials on up-
front ASCT in PTCL, 3-year OS rates of 73 [14], 48 [15] and
56 % [16] were observed.
The monoclonal antibody alemtuzumab targeting the CD52
molecule on B and T cells [17] is an attractive candidate for
treatment optimization. Although CD52 expression on malig-
nant T cells varies considerably [18], this antibody showed
promising activity in trials of various T cell lymphomas [19–
22]. However, its use is complicated by severe opportunistic
infections. Reduction of dose and treatment duration has been
shown to decrease these complications without compromising
the antitumor effect [23].
The rationale of the prospective multicenter phase II
DSHNHL 2003–1 study was therefore to combine CHO(E)P-
14, an effective chemotherapy for PTCL, with alemtuzumab.
The antibody was given to patients in complete response/
unconfirmed complete response (CR/CRu) or partial response




The study (NCT Nr. 01806337) was conducted according to
the Declaration of Helsinki and approved by the ethics com-
mittees of the participating institutions. Patients were enrolled
between July 2003 and July 2006 after written informed con-
sent. Inclusion criteria were age 18–70 years, Eastern Cooper-
ative Oncology Group (ECOG) 0–3, previously untreated ag-
gressive PTCL (all IPI), histology of PTCL-NOS (including the
lymphoepitheloid Lennert’s variant), AITL, ALK-ALCL and
enteropathy-associated intestinal T cell lymphomas (EATL).
ALK+ALCL and extranodal T/NK cell lymphomas were
excluded as well as patients with major organ dysfunctions
other than lymphoma-related, bone marrow infiltration >25 %
(quantified by flow cytometry in case of morphological posi-
tivity), a history of tuberculosis and overt cytomegalovirus
(CMV)-infection, active hepatitis, HIV-positivity, other uncon-
trolled infections, additional neoplasms and previous radio-
chemotherapy. Histological diagnosis was reviewed by a panel
of expert haematopathologists.
Treatment schedule
Staging included physical examination, routine laboratory
testing, computed tomography scan of neck, chest and abdo-
men and bone marrow biopsy. Bulky disease was defined as
the presence of a tumour mass ≥7.5 cm. A planned complete
restaging repeating all of the primary investigations (bone
marrow biopsy only in case of involvement) was performed
after six chemotherapy cycles (restaging 1). The International
Workshop criteria were used for response assessment [24].
After prephase treatment (prednisolone/vincristine), patients
<60 years received 6 cycles of CHOEP-14, patients >60 years
6×CHOP-14 [25], supported by pegfilgrastim 6 mg. Patients
with no change (NC) or progression (PRO) went off study.
Patients with CR/CRu or PR after chemotherapy received
alemtuzumab consolidation (133 mg over 4 weeks) starting
3–6 weeks after the end of chemotherapy. The first three doses
were administered intravenously on days 1–3 with dose esca-
lation (3, 10, 30 mg; premedication with clemastin, paraceta-
mol, prednisolone), the following three doses (30 mg) subcu-
taneously once per week. Prophylaxis against Pneumocystis
jirovecii and herpes infections was mandatory and was con-
tinued until CD4-cells >200/μl. Patients with positive CMV
serology were monitored weekly (pp65, CMV-PCR). Four
weeks after completion of the consolidation, a restaging was
performed as described above (restaging 2). Patients not receiv-
ing alemtuzumab due to reasons other than insufficient chemo-
therapy response also underwent restaging 2. During the
follow-up visits (years 1–2: every 3 months, years 3–5: every
6 months), patients were monitored by physical examination,
routine laboratory testing and CT scans (every 6 months).
Statistical analysis
Primary endpoint was the feasibility of alemtuzumab consol-
idation after a full course of CHO(E)P with assessment of
relative dose and toxicity. Secondary endpoints were rate of
remission, primary progression, number of patients receiving
alemtuzumab, therapy-related mortality, EFS and OS, calcu-
lated as the time from registration to the first reported event
(PRO, initiation of salvage therapy, additional (unplanned)
treatments, relapse or death of any cause) or censored at the
most recent assessment date. The analysis was planned as
intention-to-treat (ITT) with an additional per protocol analy-
sis (PP) of patients with fulfilled inclusion criteria. The trial
was designed to include at least 24 patients with reference
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diagnosis PTCL-NOS/AITL, receiving alemtuzumab after a
full course of chemotherapy. Forty-one patients were regis-
tered to allow reliable estimations of the primary endpoint for
patients receiving alemtuzumab and to estimate e.g., the
complete remission rate for patients with alemtuzumab with
a precision of ±18 %. Survival curves were compared with
log-rank tests. Relative doses were estimated according to
Kaplan–Meier [25]. The significance level was p =0.050.
Statistical analyses were done with SPSS PASW 18.
Results
Patients’ characteristics
Forty-one patients were recruited from 20 institutions and
included in the ITT analysis (Table 1). A PP analysis was
performed on 37 patients excluding those with incorrect
reference histologies: three ALK+ALCL and one extranodal
NK cell lymphoma. A considerable number presented with
unfavourable prognostic features. Stage III/IV and elevated
LDH were more often found in the older cohort. The latter
was also more frequent in patients who later did not qualify
for alemtuzumab consolidation, whereas other risk factors,
such as bulky disease and bone marrow involvement, were
present at a higher rate in the alemtuzumab group.
Treatment feasibility
The median duration of the first 5 cycles of CHO(E)P-14 was
only slightly longer than planned (77 versus 70 days) with
median relative doses of 99.4, 99.8 and 100 % for cyclophos-
phamide, doxorubicin and etoposide. Dose reduction of vincris-
tine was more frequent in the cohort >60 years, where 24.5 %
received less than the complete dose of 6×2 mg (6.8 % for
<60 years). In the majority of the patients (70.8 %), growth
factor support was performed with 6 mg pegfilgrastim
according to the study protocol, in some cases substituted by
equivalent doses of other G-CSF preparations (23%, type of G-
SCF unknown in 6.2 %) without any difference between the
age groups. Thirty-five patients (85.4 %) received all of the
planned six chemotherapy cycles (81.5 %<60 versus 92.9 %
>60 years). In six patients, chemotherapy was stopped earlier,
predominantly due to early progression (see below and Fig. 1).
Therapywith alemtuzumabwas started between days 22 and 59
after the end of chemotherapy (median, 34 days) with a median
duration of 23 days. Most of the 29 patients qualifying
for alemtuzumab (see below) received the planned total dose
of 133 mg at the projected time points. Reasons for dose
reduction were CMV reactivation (1), severe skin reaction (1)
and progression (1). A higher dose was given accidentally to
one patient (226 mg).
Treatment response
The rate of CR/CRu or good PR after chemotherapy (restaging
1) was 80.5 % (33/41 patients). Eight patients (19.5 %) did not
respond sufficiently, four of them showing PRO or NC either
early during chemotherapy or shortly afterwards (Fig. 1). They
continued treatment off study with various salvage protocols,







Male 18 (66.7 %) 8 (57.1 %) 26 (63.4 %)
Female 9 (33.3 %) 6 (42.9 %) 15 (36.6 %)
Age, median (range) 50 (19, 59) 67 (63, 70) 55 (19, 70)
Age >60 years 14 (34.1 %)
LDH>UNV 9 (33.3 %) 11 (78.6 %) 20 (48.8 %)
ECOG>1 1 (3.7 %) 2 (14.3 %) 3 (7.3 %)
ECOG 0 15 (55.6 %) 3 (21.4 %) 18 (43.9 %)
ECOG 1 11 (40.7 %) 9 (64.3 %) 20 (48.8 %)
ECOG 2 1 (3.7 %) 2 (14.3 %) 3 (7.3 %)
ECOG 3/4 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Stage III/IV 14 (51.9 %) 12 (85.7 %) 26 (63.4 %)
Stage I 6 (22.2 %) 1 (7.1 %) 7 (17.1 %)
Stage II 7 (25.9 %) 1 (7.1 %) 8 (19.5 %)
Stage III 7 (25.9 %) 8 (57.1 %) 15 (36.6 %)
Stage IV 7 (25.9 %) 4 (28.6 %) 11 (26.8 %)
Extranodal involvement>1a 5 (18.5 %) 2 (14.3 %) 7 (17.1 %)
Extranodal involvementa 11 (40.7 %) 8 (57.1 %) 19 (46.3 %)
IPIa 0, 1 16 (59.3 %) 0 (0.0 %) 16 (39.0 %)
2 8 (29.6 %) 2 (14.3 %) 10 (24.4 %)
3 3 (11.1 %) 11 (78.6 %) 14 (34.1 %)
4, 5 0 (0.0 %) 1 (7.1 %) 1 (2.4 %)
Bulky disease 4 (14.8 %) 1 (7.1 %) 5 (12.2 %)
B symptomsb 9 (34.6 %) 7 (50.0 %) 16 (40.0 %)
BM involvement 4 (14.8 %) 2 (14.3 %) 6 (14.6 %)
Histopathology
PTCL-unspecified (NOS) 21 (51.2 %)
AITL 11 (26.8 %)
Lennert’s variant 3 (7.3 %)
ALCL, ALK+c 3 (7.3 %)
ALCL, ALK− 1 (2.4 %)
Extranodal NK/Tc 1 (2.4 %)
Enteropathy-associated 1 (2.4 %)
PTCL (NOS) peripheral T cell lymphoma not otherwise specified, AITL
angioimmunoblastic T cell lymphoma, ALCL anaplastic large cell lym-
phoma, ALK anaplastic lymphoma kinase, NK natural killer
a BM involvement is counted as extranodal involvement
b One missing value
c Reference histology not meeting the inclusion criteria according to
primary pathology
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from conventional salvage regimens to allogeneic stem cell
transplantation.
Altogether, 12 patients (29.3 %) did not qualify for alemtu-
zumab (Fig. 1). Apart from the eight with insufficient re-
sponse, the reasons were patient’s refusal (1), severe skin
exanthema after chemotherapy (1) and reference histology of
ALK+ALCL (1). One patient with stage IA disease chemo-
therapy achieved a CR after three cycles of CHOEP and was
treated with involved field irradiation.
The remaining 29 patients (70.7 %) received alemtuzumab
consolidation. Among them were two with the retrospective
diagnosis of ALK+ALCL and one extranodal NK/T, nasal
type, which was unknown at the time of response evaluation
after chemotherapy. There was a 60.9 % remission rate at
restaging 2 after completion of thewhole therapy (ITT, Table 2)
with 24 patients still in CR/CRu and one patient remaining in
the same status of good PR as after induction chemotherapy.


















12 (29.3%) 29 (70.7%)Fig. 1 Treatment schedule and
clinical course (PRO progressive
disease, NC no change, for































































































Fig. 2 Survival (ITT population,
n =41) a EFS according to age
groups. b OS according to age
groups. c EFS and OS in the
whole population. d EFS and OS
in patients with alemtuzumab
consolidation (n =29)
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relapsed, two of them under or immediately after alemtuzumab,
two of them without (refusal, skin reaction, see above). Con-
sidering the whole observation time, relapses (ITT) tended to be
more frequent in patients >60 years and there was a non-
significant trend to better EFS and OS at 3 years for patients
≤60 years (Fig. 2a, b). In the PP analysis, the EFS at 3 years was
31.4 % [16.3; 46.5 % (95 % confidence interval)] and the OS
was 63.9 % [48.2; 79.6 %], thus not essentially different from
the complete ITT population (Fig. 2c, d). There was no param-
eter segregating patients with a good response to chemotherapy
and consecutive alemtuzumab consolidation from those with
the opposite outcome. Neither sex, age, histology nor the
established prognostic markers, such as LDH, IPI, extranodal
involvement, were essentially different. For these selected
patients who actually received alemtuzumab, the rates for
EFS (42.4 % [95 % CI, 23.8–61.0 %]) and OS (75.1 %
[95 % CI, 59.0–91.2 %]) were clearly higher than in the whole
cohort.
After a median observation time of 46 months, 19 (46.3 %)
patients have died. Death was mostly due to lymphoma (13)
and/or salvage therapy complications (3). In two patients,
lymphoma was complicated by cardiovascular disease and
chronic pseudomembranous colitis following CHOEP che-
motherapy requiring surgical intervention. There were three
additional deaths, the reason for one of them being unknown;
however, most probably lymphoma-related since the patient
was reported to have relapsed. The two other patients are
discussed below.
Treatment toxicity
Adverse events during the initial chemotherapy were compa-
rable to those observed in earlier studies with CHO(E)P-14.
Haematotoxicity was the predominant complication with
slightly higher rates in the younger group due to addition of
etoposide.
The application of alemtuzumab was generally well toler-
ated. One patient suffered from a severe skin reaction leading
to dose reduction, the other patients did not experience any
acute grade 3–4 toxicities. Leukocytopenia was the main
haematological toxicity. Leukocyte counts <2,000/μl were
observed in three patients, two requiring G-CSF support. There
was no severe thrombocytopenia or anaemia. Four patients
suffered from grades 3–4 infections between 1 and 6 weeks
after the last alemtuzumab application: three pneumonias due to
Aspergillus spp. and Candida albicans (1) and CMV (2). The
fourth patient presented with Gram-negative sepsis following
tooth extraction without antibiotic prophylaxis. There were also
several less severe infections: Herpes zoster infection 3 weeks
after alemtuzumab (1), asymptomatic CMVreactivation during
Table 2 Treatment outcome
(ITT population, median
observation time 46 months)
a 95 % confidence interval
b Response after the complete
sequence of therapy, including
all patients, also those having
not received alemtuzumab due to
NC/PRO under chemotherapy
or other reasons (see “Treatment
response”)
c All patients classified as having
CR/Cru at restaging 2 after the
complete sequence of therapy
≤60 years (n =27) >60 years (n =14) Total (n =41)
Response after completion of therapyb
CR/CRu 16 (59.3 %) 8 (57.1 %) 24 (58.5 %)
[38.8 %; 77.6 %]a [28.9 %; 82.3 %]a [42.1 %; 73.7 %]a
PR 0 (0.0 %) 1 (7.1 %) 1 (2.4 %)
[0.0 %; 12.8 %]a [0.2 %; 33.9 %]a [0.1 %; 12.9 %]a
NC 4 (14.8 %) 0 (0.0 %) 4 (9.8 %)
[4.2 %; 33.7 %]a [0.0 %; 23.2 %]a [2.7 %; 23.1 %]a
PRO 7 (25.9 %) 5 (35.7 %) 12 (29.3 %)
[11.1 %; 46.3 %]a [12.8 %; 64.9 %]a [16.1 %; 45.5 %]a
Relapse in CR/CRuc 5/16 (31.3 %) 4/8 (50.0 %) 9/24 (37.5 %)
[11.0 %; 58.7 %]a [15.7 %; 84.3 %]a [18.8 %; 59.4 %]a
Survival (36 months)
EFS 38.5 % 21.4 % 32.3 %
[19.5 %; 57.5 %]a [0.0 %; 43.0 %]a [17.6 %; 47.0 %]a
OS 73.3 % 41.7 % 62.4 %
[56.2 %; 90.4 %]a [15.2 %; 68.2 %]a [47.3 %; 77.5 %]a
Deaths
Total 11/27 (40.7 %) 8/14 (57.1 %) 19/41 (46.3 %)
Lymphoma-related 7/11 (63.6 %) 6/8 (75.0 %) 13/19 (68.4 %)
Salvage therapy-related 2/11 (18.2 %) 1/8 (12.5 %) 3/19 (15.8 %)
Potentially therapy-related 1/8 (12.5 %) 1/19 (5.3 %)
Sec. neoplasm 1/11 (9.1 % – 1/19 (5.3 %)
Unknown 1/11 (9.1 %) – 1/19 (5.3 %)
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alemtuzumab (3) and fever of unknown origin (1). All patients
recovered with appropriate therapy. Eight months after the end
of alemtuzumab, there was one fatal course of infection which
was potentially treatment-related. This 70-year-old patient,
initially with stage IV PTCL-NOS and splenic involvement,
experienced prolonged leukopenia following alemtuzumab.
Two months after the last restaging, reported as CR, he died
from fungal pneumonia with CMV reactivation complicated
by cardiac and hepatic failure. One patient developed acute
myeloid leukemia (AML) 20 months after completion of
therapy with CHOEP and alemtuzumab while still in CR.
He died from this disease 13 months later. EBV-related lym-
phomas were not reported.
Discussion
We could demonstrate that alemtuzumab consolidation after a
complete chemotherapy for PTCL was feasible, and nearly all
patients received the planned dose of 133 mg within the
projected time frame. Grades 3–4 infections were seen in four
patients; however, all of them were manageable and with
complete recovery. Of note, CMV-pneumonias occurred in
spite of close clinical follow-up and CMVmonitoring. One of
these patients showed grade 3 leukopenia requiring prolonged
support with G-CSF and relapsed after several months. The
second, still in CR after 46 months, had excessively low CD4-
counts remaining <200/μl for almost 1 year. While there is no
obvious correlation between relapse and infections in these
two cases, the third case of a mixed fungal pneumonia sug-
gests that profound immunosuppression due to disease pro-
gression may have contributed to this severe complication.
Although in CR at restaging 1 after chemotherapy, the patient
who initially had a widely disseminated EATL experienced a
fulminant relapse only 2 weeks after recovery from the pneu-
monia and died shortly afterwards.
No treatment-related death occurred during alemtuzumab
application and until 8 months later. There was one fatal
course of a 70-year-old patient who died from pneumonia
8 months after the end of therapy. Although persistently low
leukocyte counts have certainly contributed to the severe
infection, immunosuppression by an incipient lymphoma re-
lapse cannot be excluded. The patient showed high-risk
criteria for relapse, the last staging was 2 months ago and a
postmortem work-up was not done. Thus, it is difficult to
decide whether this death represents a late complication of
therapy or is due to the underlying illness.
As another potential late treatment effect, we observed one
case of AML in a younger patient receiving CHOEP-14 and
alemtuzumab. Since etoposide is known to increase the inci-
dence of secondary AML, this was probably a consequence of
chemotherapy rather than of alemtuzumab.
Other trials chose a strategy of concomitant chemotherapy
and alemtuzumab. Combination of either CHOP-28 or −21
with alemtuzumab (30 mg/cycle) led to frequent severe infec-
tions with two treatment-related deaths [26, 27]. The added
effect of alemtuzumab with a total dose almost twice as high
as in our study may explain the distinctly higher rate of serious
infections. Combination of alemtuzumab (70 mg/cycle) with a
fludarabine-containing regimen induced even higher infec-
tious toxicities and six treatment-related deaths [28]. Notably,
two cases of EBV-associated lymphoproliferative disease
(LPD) were observed several months after therapy. The same
phenomenon was encountered in the HOVON study [29],
combining CHOP-14 with a very high dose of alemtuzumab
(90 mg/cycle). Despite the rather long observation period,
there was no such event in our study. This suggests that the
total dose of alemtuzumab and/or the timing of alemtuzumab
application is critical in this regard.
The potential influence of alemtuzumab on the treatment
outcome is difficult to assess. The higher EFS and OS rates
(42.4 and 75.1%) in our alemtuzumab cohort may only reflect
the selection effect after omission of those patients who did
not respond sufficiently to the initial chemotherapy. Interest-
ingly, a recent study of the GOELAMS group observed sim-
ilar rates with 41 % EFS at 2 years after CHOP-21 alone [30].
Nevertheless, the high overall remission rates achieved by
high alemtuzumab doses concomitant to chemotherapy, rang-
ing between 63 and 90 % [26–29], suggest an added effect.
They are higher than in the present study. However, presum-
ably due to the increased rate of side effects, the outcome
regarding survival is not essentially different. A 2-year OS and
EFS of 53 and 48 % [26] as well as of 55 and 27 % [29] were
reported for 30 and 90 mg alemtuzumab per chemotherapy
cycle, while OS and EFS in our study were 62.4 and 32.3 % at
3 years.
Surprisingly, this is more or less within the same range as
observed with myeloablative protocols [14, 15] although the
cytotoxic dose of chemo- and/or radiotherapy in these studies
was much higher and the patients clearly younger. Recently,
the Nordic Lymphoma Group has reported the final results of
the NGT-T-01 trial [16], investigating dose-dense CHO(E)P
followed by high-dose chemotherapy and ASCT in treatment-
naïve PTCL patients. Although OS rates are confounded by
secondary regimens up to allogeneic stem cell transplantation,
the 3-year OS (56 %) was not higher than in our study. The
3-year-EFS (32.3 %) used as a secondary endpoint in our study
is difficult to compare with TTF and PFS rates since it is based
on different criteria. However, the 3-year TTF of 41 % in the
NGT-T-01 trial seems promising and may be explained by the
relatively high amount of included ALK-ALCL (19 versus
2.4 % in our study), anaplastic histology being associated with
significantly better outcome.
We conclude that CHO(E)P-14 followed by a short course
of alemtuzumab consolidation is a feasible therapeutic option.
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Infectious complications are partially severe but mostly man-
ageable and require particular attention. Due to the design of the
study, the data do not allow the assessment of the alemtuzumab
effect on treatment outcome. However, although representing a
selected cohort with favourable characteristics, remission and
survival rates in those patients receiving the complete
immunochemotherapy are encouraging and comparable to
those of more intensive regimens. To definitely clarify if and
to what extent the different biological anti-tumour approach of
alemtuzumab contributes to the therapeutic outcome, the results
of randomized studies such as the current intergroup ACT trials
are to be awaited.
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